High risk population screening for Fabry disease in hemodialysis patients in Vojvodina: Pilot study

• Published in: Srpski arhiv za celokupno lekarstvo Vol. 150; no. 5-6; pp. 281 - 287
• Main Authors: Celic, Dejan, Pavlovic, Sonja, Skakic, Anita, Vucenovic, Jelica, Pilipovic, Dragana, Golubovic, Sonja, Stojsic, Tatjana, Milicevic, Olivera, Vojinovic, Goran, Dudic, Svetlana, Petrovic, Lada, Mitic, Igor
• Format: Journal Article
• Language: English
• Published: Serbian Medical Society 01-05-2022
• Subjects: fabry disease; hemodialysis; high-risk population screening
• ISSN: 0370-8179; 2406-0895
• DOI: 10.2298/SARH211103037C

Introduction/Objective. Fabry disease (FD) is an X-linked lysosomal storage disease that develops as a consequence of mutation in the alpha-galactosidase A (GLA) gene. There are more than 1080 known variants in the GLA gene. Some of them are pathogenic, but most of them are benign or represent the genetic change that can be classified as a genetic variant of unknown significance or simply be a representation of genetic polymorphism. There are two main features of FD, classic form and late-onset variants of disease. The main target organs in patients with FD are the kidneys, heart, and nervous system. Bearing in mind the fact that FD is a rare disease, the best way for active searching of patients is high-risk population screening, after which family screening for every proband case should be performed. Methods. In this paper, we present results of a multicentric pilot study that represents findings from the screening of hemodialysis patients for FD in six hemodialysis units in Vojvodina. Results. We have found one patient with benign mutation and 16 patients with genetic polymorphisms in GLA gene. We have learned that genetic changes in GLA gene can be frequent, but very rarely are of clinical significance and lead to manifestations of FD. Conclusion. Results of this screening study will give us important insights into our future work.